Bactofencin A, a New Type of Cationic Bacteriocin with Unusual Immunity

Eileen F. O’Shea, Paula M. O’Connor, Orla O’Sullivan, Paul D. Cotter, R. Paul Ross, Colin Hill

ABSTRACT  Bacteriocin production is an important probiotic trait of intestinal bacteria. In this study, we identify a new type of bacteriocin, bactofencin A, produced by a porcine intestinal isolate Lactobacillus salivarius DPC6502, and assess its potency against pathogenic species including Staphylococcus aureus and Listeria monocytogenes. Genome sequencing of the bacteriocin producer revealed bfnA, which encodes the mature and highly basic (pI 10.59), 22-amino-acid defensin-like peptide. Matrix-assisted laser desorption ionization–time of flight (MALDI-TOF) mass spectral analysis determined that bactofencin A has a molecular mass of 2,782 Da and contains two cysteine residues that form an intramolecular disulfide bond. Although an ABC transporter and transport accessory protein were also present within the bacteriocin gene cluster, a classical bacteriocin immunity gene was not detected. Interestingly, a dltB homologue was identified downstream of bfnA. DltB is usually encoded within the dlt operon of many Gram-positive bacteria. It is responsible for D-alanylation of teichoic acids in the cell wall and has previously been associated with bacterial resistance to cationic antimicrobial peptides. Heterologous expression of this gene conferred bacteriocin A-specific immunity on sensitive strains of L. salivarius and S. aureus (although not L. monocytogenes), establishing its role in bacteriocin immunity. An analysis of the distribution of bfnA revealed that it was present in four additional isolates derived from porcine origin and absent from five human isolates, suggesting that its distribution is host specific. Given its novelty, we anticipate that bactofencin A represents the prototype of a new class of bacteriocins characterized as being cationic, with a DltB homologue providing a cognate immunity function.

IMPORTANCE  This study describes the identification, purification, and characterization of bacteriocin A, a novel type of bacteriocin produced by L. salivarius DPC6502. Interestingly, bacteriocin A is not similar to any other known bacteriocin but instead shares similarity with eukaryotic cationic antimicrobial peptides, and here, we demonstrate that it inhibits two medically significant pathogens. Genome sequence analysis of the producing strain also revealed the presence of an atypical DltB homologue in the bacteriocin gene cluster, which was lacking a classical bacteriocin immunity gene. Furthermore, cloning this gene rendered sensitive strains resistant to the bacteriocin, thereby establishing its role in providing cognate bacteriocin immunity. Four additional L. salivarius isolates, also of porcine origin, were found to contain the bacteriocin biosynthesis genes and successfully produced bactofencin A, while these genes were absent from five human-derived strains investigated.

The genus Lactobacillus consists of more than 145 species whose habitats range from soil and plants to the mammalian gastrointestinal tract (GIT) (1). These bacteria produce a rich diversity of bacteriocins in terms of structure and mode of action, varying from extensively posttranslationally modified lantibiotics such as plantaricin C (2) to large, unmodified, heat-labile proteins such as helveticin J (3).

Lactobacillus salivarius is a species particularly associated with the mammalian GIT (4–7), and many associated probiotic attributes, including favorable immunomodulatory, antiinflammatory, and antiinfective properties, have been associated with specific strains (8). Indeed, due to its positive immunomodulatory and potent antimicrobial activity, one strain of L. salivarius was among six strains chosen to formulate a multispecies probiotic for combating disease in critically ill patients (9). The L. salivarius component of another five-strain probiotic combination, L. salivarius DPC6005, outcompeted four coadministered strains to dominate within the porcine ileal digesta and mucosa (10). In addition, the antistaphylococcal activity of L. salivarius CECT 5713, isolated from a mother and child pair (7), indicated that this strain is an alternative to conventional antibiotics in the treatment of infectious mastitis in women during lactation (11, 12). Further studies with this strain have highlighted its immune-modulatory properties and its safety with respect to human consumption (13–15).

The range of bacteriocins produced by L. salivarius extends from the class IIa pediocin-like bacteriocins OR-7 and L-1077 (16, 17) to the two-component class IIb bacteriocins abp118, salivari-
cin P, salivaricin T, and variants (4, 18–23) and the class IId linear non-pediocin-like bacteriocins, such as salivaricin B and salivaricin L (24, 21). Each of these bacteriocins has demonstrated inhibitory activity toward medically significant pathogens. Notably, purified bacteriocin OR-7 and L-1077 have provided in vivo protection against Campylobacter jejuni and Salmonella enterica serovar Enteritidis infection in chickens (16, 17). Moreover, Corr et al. demonstrated abp118-mediated protection against Listeria monocytogenes infection in mice upon administration of the producing strain L. salivarius UCC118, thereby substantiating the role of bacteriocins in mediating a probiotic effect (61). It is feasible that these bacteriocins could be exploited for the therapeutic manipulation of the intestinal flora. Indeed, the influence of abp118 on the composition of the gut flora of diet-induced obese (DIO) mice and pigs following the administration of the producing strain has also been demonstrated recently (25, 26).

In this study, we describe an unusual bacteriocin, bactofencin A, produced by the porcine intestinal isolate L. salivarius DPC6502. The bacteriocin locus encodes a highly basic antimicrobial peptide of just 22 amino acid residues, and in this respect, bactofencin A bears a close resemblance to certain eukaryotic cationic antimicrobial peptides. Moreover, a DltB homologue confers on the producing strain specific immunity to bactofencin A, suggesting a role for teichoic acid in the immunity mechanism. Genes encoding this bacteriocin have been identified in several porcine isolates but appear to be absent from human L. salivarius isolates.

RESULTS

The isolation of L. salivarius DPC6502, which has broad-spectrum antimicrobial activity, from porcine jejunal digesta has been described previously (27). While PCR assays initially suggested that this strain produces a variant of abp118, recent array-based comparative genomic hybridization (aCGH) analyses revealed the absence of abp118-related homologues in strain DPC6502 (21). Indeed, this strain was the most divergent of seven L. salivarius test strains when compared with the genome of the reference strain L. salivarius UCC118 (28), exhibiting just 78% conservation of strain UCC118-specific gene content (21). Its potent antimicrobial activity and considerable genetic divergence led to the further characterization of strain DPC6502 and the associated antimicrobial activity.

Characterization of the antimicrobial phenotype of L. salivarius DPC6502. The peptide responsible for the antimicrobial activity of L. salivarius DPC6502 was purified from an overnight culture of the strain using cation exchange followed by reversed-phase chromatography. Subsequent matrix-assisted laser desorption ionization–time of flight mass spectrometry (MALDI-TOF MS) analysis revealed an associated mass of 2,782 Da in the active fractions (Fig. 1). Edman analysis revealed the N-terminal sequence KRKXHRXRVYNNGMPTGMYRYM, where “X” at positions 4 and 7 indicates blank cycles for which no amino acid derivative was detected. A homology search did not identify any similar sequences in protein databases. The purified bacteriocin peptide inhibited closely related lactobacilli, as well as Staphylococcus aureus and, to a lesser extent, Listeria innocua (Fig. 1).

Considering the unusual nature of this bacteriocin, the genome of the producing strain L. salivarius DPC6502 was sequenced to identify the corresponding gene cluster.

Characterization of the bacteriocin locus in the genome of L. salivarius DPC6502. Scanning of the entire draft genome sequence for a gene corresponding to the N-terminally derived amino acid sequence revealed a chromosomally located open reading frame (ORF), DLSL_0050, present on a gene cluster which was absent from the publically available L. salivarius genome sequences. The unidentified amino acids at positions 4 and 7 in the sequence determined by Edman degradation were, on the basis of the corresponding codons, found to be lysine and cysteine residues, respectively (Fig. 2). The bacteriocin structural gene consists of 159 nucleotides and is predicted to encode a 53-amino-acid (aa) precursor peptide comprised of a 31-aa double-glycine leader sequence and a 22-aa propeptide sequence which differed from that
Bactofencin A, a Defensin-Like Bacteriocin

Figure 2

**FIG 2** Nucleotide sequence and deduced peptide sequence of the structural gene of bactofencin A. The leader sequence is underlined, and the GG-processing site is indicated by an arrowhead. The bacteriocin structural gene and predicted immunity gene and transport genes are indicated by black, white, and gray arrows, respectively.

derived by peptide sequencing with respect to the two most C-terminally located residues (Fig. 2). The predicted mass of the mature translation product (2,785 Da) differed from that determined by MALDI-TOF MS analysis of the active peptide (2,782 Da) by 3 Da. MS analysis revealed an increase of 2 Da (2,784 Da) in the mass of the active peptide when the cysteine residues were in a reduced state (after treatment with dithiothreitol [DTT] and iodoacetamide), indicating that an intramolecular disulfide bond is formed between Cys7 and Cys22. A search of the BLAST database did not identify any homologues for this ORF, indicating that this peptide is unlike any previously characterized bacteriocins. However, a search of the antimicrobial peptide database (29) revealed that bactofencin A shares the greatest similarity (42%) with a plant antimicrobial peptide (AMP) isolated from extracts of the seed of *Impatiens balsamina* (Ib-AMP3) which displays both antibacterial and antifungal properties (30). In consequence of the greater similarity of this bacteriocin to cationic peptides of eukaryotic origin, it was designated bactofencin A. Despite its similarity to Ib-AMP3, neither *L. salivarius* DPC6502 nor the purified bactofencin A peptide exhibited antifungal activity against the indicator strains investigated (data not shown).

The ORF immediately downstream from the bacteriocin structural gene (*bfnA*) encodes a putative protein of 396 aa which shares 74% identity with an operon-encoded D-alanyl transfer protein (DltB) of *Pediococcus pentosaceus* ATCC 25745 (accession no. YP_805052) and 65% identity with the operon-encoded DltB of *L. salivarius* UCC118 (LSL_0891). DltB is a transmembrane protein responsible for the transfer of activated D-alanine across the cytoplasmic membrane, which is indispensable for the D-alanyl esterification of teichoic acids (31, 32). Interestingly, D-alanylation of teichoic acids has previously been found to contribute to bacterial resistance to cationic antimicrobial peptides due to the resultant reduction in the net negative charge generated in the bacterial cell wall, thereby attenuating essential electrostatic interactions (32–36). A second DltB-encoding gene (DLSL_0976), present in a dlt operon (DLSL_0974 to DLSL_0978), is also located on the chromosome of *L. salivarius* DPC6502, the product of which shares 99% identity with DltB of UCC118 (encoded by LSL_0891) and 65% identity with the deduced protein product of DLSL_0051. The ORFs downstream from the *dltB* homologue encode a putative bacteriocin ABC transporter (DLSL_0052) and a bacteriocin transport accessory protein (DLSL_0053). The deduced protein sequence of the ABC transporter contains an N-terminal peptidase C39 domain of 139 aa which contains a conserved cysteine motif and histidine motif characteristic of the putative catalytic site responsible for the cleavage of double-glycine leader sequences (37, 38). Thus, these genes encode proteins which are probably responsible for the processing and secretion of the mature active bactofencin A. This putative bacteriocin transport system likely completes the bacteriocin gene cluster (approximately 4 kb), as the adjacent ORFs, which are conserved in UCC118 (LSL_0035 to LSL_0042), display similarity to the WalRK (YycGF) regulon responsible for the regulation of bacterial cell wall metabolism of low-G+C Gram-positive bacteria (39).

**Bactofencin A is active at micromolar concentrations.** The identification of the structural gene and deduced peptide sequence facilitated the production of synthetic bactofencin A. MS analysis revealed a mass of 2,784 Da for the synthetic form of the peptide, which displayed anti-*Listeria* and anti-*S. aureus* activity that was similar to that of the purified natural bactofencin A peptide (data not shown). This suggests that the disulfide bond of the natural form of bactofencin A is not crucial for activity. In consequence of this and of the fact that the synthetic approach provided access to larger quantities of peptide, the synthetic bactofencin A peptide was employed for further antimicrobial activity assays, which on this occasion took the form of more-sensitive broth-based MIC₅₀ assays. These investigations revealed that, although concentrations of up to 50 μM of synthetic bactofencin A did not inhibit *Escherichia coli*, *Cronobacter sakazakii*, *Salmonella*, or any of the fungal indicator strains employed, concentrations of 1 to 5 μM were sufficient to inhibit the growth of both *S. aureus* DPC5246 and *L. monocytogenes* NCTC 11994 (Fig. 3). Furthermore, the bactericidal effect of bactofencin A was demon-

![Figure 3](image-url)
encoded by the ORF immediately downstream of \textit{bfnA}, designated \textit{bfnI}, has a role in bacteriocin \textit{A} immunity, an expression plasmid (pEO501) harboring \textit{bfnI} was constructed. When introduced into the sensitive indicator strains \textit{L. monocytogenes} NCTC11994 and \textit{S. aureus} DPC5246, a statistically significant increase in resistance to bacteriocin \textit{A}, relative to the resistance of the corresponding isogenic control strains harboring the pNZ44 plasmid, was evident for transformants of the \textit{S. aureus} DPC5246 indicator strain (Fig. 5) but not for those of the \textit{L. monocytogenes} NCTC11994 strain (data not shown). Moreover, introducing the pEO501 construct into the more-similar, yet sensitive strain \textit{L. salivarius} UCC118 resulted in almost-complete immunity to the bacteriocin for the corresponding transformants relative to the control (Fig. 5B). However, this resistance was specific for bacteriocin \textit{A}, as these clones did not exhibit enhanced resistance when exposed to a range of cationic antimicrobial peptides, suggesting that the protection provided is not due to a general impact on cell wall charge (Fig. 6).

The results of cytochrome \textit{c} binding assays also correlated with these results. Cytochrome \textit{c} is a highly positively charged protein (pI 10), readily detected at 530 nm, whose binding is dependent on the net negative cell surface charge. In a control study, following a 10-min exposure, the level of unbound cytochrome \textit{c} detected in the cell-free supernatant (CFS) of the \textit{dltA}-deficient \textit{S. aureus} Sa113 mutant was considerably lower than the level in the CFS of the wild-type strain. This indicates an increase in the net negative cell surface charge of the mutant relative to that of the wild-type

![Graph showing viability of S. aureus DPC5246 treated with and without synthetic bactofencin A as a function of time.](image)

**FIG 4** Viability of \textit{S. aureus} DPC5246 treated with (black squares) and without (open circles) synthetic bactofencin A as a function of time. These results represent the average of three independent experiments. Error bars represent standard errors based on triplicate data.

A \textit{DltB} homologue is responsible for bacteriocin \textit{A}-specific immunity. Typically, the unmodified class II bacteriocin structural genes are cotranscribed with an ORF encoding a cognate immunity protein, usually 50 to 150 aa in size and located downstream of the structural gene, which provides self-protection for the producing strain. To determine whether the \textit{DltB} homologue

![Graph showing O.D. at 590 nm for S. aureus DPC5246 pNZ44 and S. aureus DPC5246 pEOS01.](image)

**FIG 5** (A) \textit{S. aureus} DPC5246 containing pEOS01 exhibits significantly enhanced resistance to bacteriocin \textit{A} relative to the resistance of the isogenic control strain at concentrations of 0.5 \textmu M (\textit{P} < 0.01), 2.5 \textmu M (\textit{P} < 0.05), and 5 \textmu M (\textit{P} < 0.05) following 24 h of incubation with the peptide. Error bars represent standard deviations based on triplicate data. (B) \textit{L. salivarius} UCC118 containing pEOS01 (ii) also exhibits enhanced resistance to bacteriocin \textit{A} relative to the resistance of the respective isogenic control strain harboring pNZ44 (i).
strain, due to the associated decrease in d-alanylation of teichoic acids (Fig. 7). However, the affinity for cytochrome c of S. aureus DPC5246 or L. salivarius UCC118 containing pEO01 did not differ from that of the respective control (Fig. 7).

The bactofencin A locus is a novel hypervariable gene cluster characteristic of L. salivarius of porcine origin. The production of similar or identical bacteriocin is frequent among genetically distinct strains or even species of lactic acid bacteria (LAB) (6, 40–42). Indeed, the genetic determinants for abp118-like bacteriocins are among the relatively high content of hypervariable gene clusters of L. salivarius (6, 21, 43). To investigate whether the bactofencin A locus described in this study is similarly among the hypervariable loci of the flexible gene pool of L. salivarius, we investigated eight additional L. salivarius isolates, four of human and four of porcine intestinal origin (Table 1), for the presence of the bactofencin A structural gene. A PCR product corresponding to this gene could not be generated from the genomic DNA of the four strains of human origin, namely, DPC6488, DPC6196, DPC6107, and DPC6095. Cross-immunity assays also revealed that each of these isolates was sensitive to the bactofencin A-producing strain. However, all four additional porcine strains (L. salivarius DPC6005, DPC6027, DPC6189, and 7.3) were immune to bactofencin A and PCR positive for bfnA. Sequencing of the PCR products generated confirmed 100% identity with the bactofencin A structural gene of DPC6502 in each case. Subsequent purification and MS analysis confirmed bactofencin A production in these strains.

**DISCUSSION**

Sequence analysis of the L. salivarius DPC6502 genome revealed that the bactofencin A structural gene is encoded on a gene cluster of approximately 4 kb which is not present in the well-characterized L. salivarius UCC118 strain. While the leader sequence –VSRRDLAVNGG of the bacteriocin prepeptide is unusually long (31 aa), it conforms with the consensus for double-glycine leaders (as highlighted in boldface) (38). The fact that its bioactivity did not require extensive posttranslational modification of the peptide and the absence of the characteristic YGNV consensus motif of pediocin-like class IIa bacteriocins suggest that this peptide belongs to the diverse class IIId bacteriocins of Gram-positive bacteria (44). Class IIId consists of a heterogenous collection of bacteriocins which cannot be assigned to any of the other known bacteriocin subgroups. The mature bactofencin A peptide is highly basic, containing eight positively charged residues that are largely concentrated at the N terminus, which may be involved in mediating the initial binding of the bacteriocin to target cells via electrostatic interaction. Database searches have revealed that this peptide does not share significant homology with previously characterized bacteriocins but more closely resembles eukaryotic antimicrobial peptides. It would thus appear that bactofencin A is the first of a novel group of bacteriocins.

Although a previous assessment of the antimicrobial activity of the producing strain, using agar well diffusion assays with neutralized CFS, revealed a broad spectrum of inhibition which included 22 of 62 indicator strains (27), this activity was found to be predominantly against closely related strains of LAB. The availability of purified bactofencin A in this study established the in vitro efficacy of the bacteriocin, revealing MIC50 values of 1 to 5 μM against the pathogenic indicator strains L. monocytogenes and S. aureus, as well as the bactericidal nature of this antimicrobial activity. This activity is comparable to that of the two-component lantibiotic lactacin 3147, which displayed a MIC50 of 7 to 8 μM for the bovine mastitis isolate S. aureus DPC5245 (45). However, the fact that bactofencin A is an unmodified bacteriocin and, thus, can be readily generated in large quantities in a synthetic form may make this novel bacteriocin a more-favorable alternative to antibiotics for animal husbandry-related applications.

Despite its uncharacteristically large size (396 aa) relative to the sizes of cognate bacteriocin immunity proteins (30 to 100 aa), the expression of bfnL enhanced the resistance of two sensitive indicator species to bactofencin A, conferring almost-complete immunity on L. salivarius UCC118. However, a statistically significant increase in bactofencin A resistance was not observed for the L. monocytogenes indicator strain, possibly due to the lower sensitivity of this strain to the bacteriocin (Fig. 3A). BfnL shares considerable homology with d-alanyl transfer proteins, which are generally encoded on the dlt operon, responsible for the d-alanylation of teichoic acids on the bacterial cell wall. Being predominantly negatively charged, teichoic acids are consequently a major determinant of the cell wall electrostatic interactions. Increased d-alanylation of teichoic acids attenuates such interactions, thereby conferring resistance to cationic antimicrobial peptides (32–36). Interestingly, S. aureus organisms harbor-

**FIG 6** The specific immunity of L. salivarius UCC118 containing pEOS01 to bactofencin A (ii) (b) relative to the resistance of L. salivarius UCC118 containing pNZ44 (i) (b) was not extended to the additional cationic antimicrobial peptides investigated, gramicidin (a), protegrin-1 (c), magainin II (d), e-polysine (f), and nisin (g).

**FIG 7** Comparison of relative net cell surface charge. The dltA-deficient S. aureus Sa113 experimental control has a higher affinity for cytochrome c than wild-type S. aureus Sa113 due to a decrease in d-alanylation of teichoic acids and a resultant decrease in the net negative cell surface charge. However, the expression of BfnL does not influence the affinity of S. aureus DPC5246 or L. salivarius UCC118 for cytochrome c relative to the affinities of their respective controls.
**TABLE 1** Bacterial strains used in this study

| Strain | Relevant features | Reference |
|--------|------------------|-----------|
| *Lactobacillus salivarius* | UCC118, Abp118 producer, human intestinal isolate | 19 |
| *Lactobacillus salivarius* | DPC6502, bactofencin A producer, porcine intestinal isolate | 27 |
| *Lactobacillus salivarius* | DPC6085, salivaricin P producer, bactofencin A producer, porcine intestinal isolate | 4 |
| *Lactobacillus salivarius* 7.3 | Salivaricin P producer, bactofencin A producer, porcine intestinal isolate | 4 |
| *Lactobacillus salivarius* DPC6189 | Salivaricin P producer, bactofencin A producer, porcine intestinal isolate | 4 |
| *Lactobacillus salivarius* DPC6027 | Salivaricin P producer, bactofencin A producer, porcine intestinal isolate | 4 |
| *Lactobacillus salivarius* DPC6488 | Salivaricin T producer, human intestinal isolate | 27 |
| *Lactobacillus salivarius* DPC6196 | Bac²⁺, despite harboring bacteriocin structural genes, human intestinal isolate | 4 |
| *Lactobacillus salivarius* DPC6095 | Bac²⁺, human intestinal isolate | 4 |
| *Lactobacillus salivarius* DPC6107 | Bac²⁺, human intestinal isolate | 4 |
| Escherichia coli XL-1 blue | Intermediate host for DNA manipulations | Stratagene |

**Microbial indicator strains**

- *Escherichia coli* DH5α
- *Escherichia coli* O157:H7 strain P1432, nontoxicigenic (Sigma, Poole, United Kingdom) was used in selective medium, being grown aerobically at 37°C in brain heart infusion (BHI) medium (Merck). Chloramphenicol Blue, used as an intermediate host for DNA manipulations, was also grown aerobically at 37°C in brain heart infusion (BHI) medium (Merck). *E. coli* XL-1 Blue, used as an intermediate host for DNA manipulations, was also grown aerobically at 37°C in LB medium (Merck). Chloramphenicol (Sigma, Poole, United Kingdom) was used in selective medium, being added at concentrations of 20 μg ml⁻¹ (*Escherichia coli*) and 5 μg ml⁻¹ (*Staphylococcus aureus*).  The indicator strains employed for antifungal characterization included *Saccharomyces cerevisiae*, *Aspergillus niger*, *Botrytis cinerea*, *Geotrichum candidum*, *Penicillium notatum*, and *Rhizopus stolonifer*. These were maintained aerobically on potato dextrose medium (Merck) at 25°C.

**MATERIALS AND METHODS**

**Bacterial and fungal strains and culture conditions.** The *L. salivarius* strains used in this study are listed in Table 1. All lactobacilli were routinely cultured under anaerobic conditions at 37°C in MRS medium (Difco Laboratories, Detroit, MI), unless otherwise stated. Anaerobic conditions were maintained with the use of anaerobic jars and AnaeroCult conditions were maintained with the use of anaerobic jars and AnaeroCult gas packs (Merck, Darmstadt, Germany). The *Escherichia coli*, *Cronobacter* (Enterobacter), *Listeria* (Enterobacter), *Listeria innocua* DPC3572 and *Listeria monocytogenes* NCTC11994 were grown aerobically at 37°C in brain heart infusion (BHI) medium (Merck). The *E. coli* XL-1 Blue, used as an intermediate host for DNA manipulations, was also grown aerobically at 37°C in LB medium (Merck). Chloramphenicol (Sigma, Poole, United Kingdom) was used in selective medium, being added at concentrations of 20 μg ml⁻¹ (*Escherichia coli*) and 5 μg ml⁻¹ (*Staphylococcus aureus*).  The indicator strains employed for antifungal characterization included *Saccharomyces cerevisiae*, *Aspergillus niger*, *Botrytis cinerea*, *Geotrichum candidum*, *Penicillium notatum*, and *Rhizopus stolonifer*. These were maintained aerobically on potato dextrose medium (Merck) at 25°C.

**Purification of the hydrophilic antimicrobial peptide produced by *L. salivarius* DPC6502.** The antimicrobial peptide was purified from a 2-liter overnight culture of *L. salivarius* DPC6502 grown in MRS medium. The cells were removed by centrifugation at 8,000 × g for 15 min, and the...
supernatant applied to a column containing 90 ml SP Sepharose fast-flow cation-exchange resin (GE Healthcare, United Kingdom) previously equilibrated with 20 mM potassium phosphate buffer, pH 2.5, containing 25% acetonitrile. The column was washed with 20 ml potassium phosphate buffer, pH 2.5, containing 25% acetonitrile, 600 mM KCl, and the bioactive peptide was subsequently eluted from the column using 20 mM potassium phosphate buffer, pH 2.5, containing 25% acetonitrile, 1 M KCl. Acetonitrile was removed by rotary evaporation before the sample was applied to a 5-g Strata-E C18 SPE column (Phenomenex, Cheshire, United Kingdom) pre-equilibrated with methanol and water. The column was washed with distilled water, and the peptide eluted with 70% (vol/vol) propan-2-ol containing 0.1% (vol/vol) trifluoroacetic acid (TFA). The propan-2-ol was removed by rotary evaporation, and 2- by 4-ml aliquots of the resultant preparation were applied to a Jupiter proteo reversed-phase high-performance liquid chromatography (RP-HPLC) column (250.0 by 10.0 mm, 4-μm particle size, 90-Å pore size; Phenomenex). The column was pre-equilibrated with 10% (vol/vol) acetonitrile containing 0.1% (vol/vol) TFA, followed by separation and elution of the bioactive peptide by gradient RP-HPLC using 0.1% (vol/vol) TFA and acetonitrile concentrations that ranged from 10% to 30% (vol/vol), over a period of 5 to 45 min at a flow rate of 2.5 ml min⁻¹. Absorbance was monitored at a wavelength of 214 nm.

Bacteriocin activity was monitored throughout the purification procedure by well diffusion assay using the sensitive indicator strain Lactobacillus delbrueckii subsp. bulgaricus LMG6901. MALDI-TOF MS (Axima-TOF²; Shimadzu Biotech, Manchester, United Kingdom) analysis was performed on bioactive fractions as described previously (48). Fractions of interest were further purified by reapplying them to the RP-HPLC column under the conditions described above. N-terminal sequence analysis of the purified antimicrobial peptide by Edman degradation was performed by Aberdeen Proteomics (University of Aberdeen, Scotland). Reduction and alkylation of the cysteine residues were performed using DTT and iodoacetamide (Sigma).

**Generation of a synthetic analogue of bactofencin A.** The bacteriocin A peptide was synthesized according to the deduced amino acid sequence (54). Each plate included triplicate assays at each concentration of synthetic bactofencin A examined. Each well contained a total volume of 200 μl, comprised of purified bactofencin A, the first component added to the well, and 150 μl of a 1-in-10 dilution of the indicator culture (A₀₉₀ of 0.1) in BH broth. Control wells contained medium only (blanks) and untreated indicator culture. The microtiter plate cultures were incubated at 37°C for 24 h, and the optical densities at 590 nm (OD₅₉₀) recorded at 30-min intervals (GENios plus; Tecan, Switzerland). Triplicate readings were averaged, and blanks were subtracted from these readings. The amount of bacteriocin that inhibited the indicator strain by 50% was defined as 50% of the final OD₅₉₀ reading ± 0.05 of the untreated control culture.

**DNA manipulations, transformation, and plasmid construction.** The DlbT homologue encoded by DLSL_0051, designated bfnI, was amplified by routine PCR using velocity DNA polymerase (Bioline, United Kingdom) and the primer pair bfnI_F, 5'-CCGGGTACCCGGAGATGT ATGTTGTGTGC 3', and bfnI_R, 5'-CGAGCTCGTTAATCATGTTTGCA ACCATAC 3', containing the restriction sites for the KpnI and SacI enzymes (underlined). Digestion facilitated insertion of the resultant product downstream from the constitutive p44 lactococcal promoter in the expression vector pNZ44 (55) to generate pEOS01. The integrity of the insert was confirmed by DNA sequencing using the primer pair pNZ44_for, 5'-TTACAGGCTACTTTGGTGTG 3', and pNZ44_rev, 5'-TGTTTAAAGCAGTAGTGCA ACCATA 3', specific for the pNZ44 multiple cloning site (56). Restriction enzymes and T4 DNA ligase (New England Biolabs, Beverly, MA) were used according to the manufacturer’s instructions. PCR products were purified using the Isolate PCR and gel kit (Bioline), and the Qiagen plasmid minikit (Qiagen, West Sussex, United Kingdom) was used to isolate plasmid DNA from E. coli transformants. E. coli, S. aureus, L. monocytogenes, and L. salivarius were transformed by electroporation in accordance with methods described previously (57–60). The sensitivities of the clones were compared to those of the control strains using the microtiter well-based assay system described above and also by well diffusion assay using 2-fold serial dilutions of bactofencin A prepared in 50 mM potassium phosphate buffer, pH 6.8. Similarly, the clones and their respective controls were assayed against the cationic antimicrobial peptides magainin II, polymyxin B, protegrin-1, e-polysine, and nisin, as well as gramicidin D, an antimicrobial of neutral charge.

**Comparison of relative net cell surface charges.** The cytochrome c binding affinity of the bfnI clones and their respective isogenic controls were measured as described previously (32). Briefly, mid-log-phase cells (with an OD₅₉₀ of 0.5) were harvested and washed twice with 20 mM MOPS (morpholinepropanesulfonic acid), pH 7. The cells were then suspended in 0.5 ml 20 mM MOPS, pH 7, and cytochrome c from equine heart (Sigma) was added at a final concentration of 0.5 mg ml⁻¹. Following a 10-min incubation at room temperature, the cells were pelleted and the unbound cytochrome c present in the supernatant was quantified spectrophotometrically at 530 nm. A control consisting of 0.5 mg ml⁻¹ cytochrome c in 20 mM MOPS, pH 7 (buffer without cells), was also included as a reference. The absorbance measurements obtained compared with that of the reference were calculated as the ratio of the absorbance recordings (reflecting the bacterial surface charge). A dfrA-deficient S. aureus Sa113
mutant and the corresponding parent strain (32) served as experimental controls. The data are representative of at least three independent studies.

**Detection of bfnA.** The presence of bfnA was determined by PCR using template DNA from eight additional genetically distinct intestinal L. salivarius isolates (Table 1) and the primer pair bfnA, 5’ CAGTCGAGAATGATCATGAGGTTACGCG 3’, and bfnAR, 5’ GGAAGTAAGTAGGTTTGTATAAGTGC 3’, to amplify a product of 430 nucleotides. This was performed using the Expand high-fidelity PCR system (Roche) according to the manufacturer’s instructions. The products derived from PCR were purified and sequenced (Beckman Coulter Genomics), and analysis of DNA sequence data was performed using Lasergene 8 software (DNASTAR, Inc., Madison, WI). Template DNA of L. salivarius DPC6502 and L. salivarius UCC118 were used as positive and negative controls, respectively. Subsequent purification and MS analyses, as described above, further confirmed positive results.

**ACKNOWLEDGMENTS**

This work was funded by the Food Institutional Research Measure of the Department of Agriculture, Fisheries and Food (grant no. 04R and DC) and the Alimentary Pharmabiotic Centre (which is funded by the Science Foundation of Ireland [SFI] through the Irish Government’s National Development Plan). We and the work were supported by SFI (grant no. 07/CE/B1368).

**REFERENCES**

1. Claesson MJ, van Sinderen D, O’Toole PW. 2008. Lactobacillus phylogenomics—towards a reclassification of the genus. Int. J. Syst. Evol. Microbiol. 58:2945–2954.

2. Wiedemann I, Bottiger T, Bonelli RR, Schneider T, Sahl HG, Martinez B. 2006. Lipid II-based antiemic activity of the lantibiotic plantaricin C. Appl. Environ. Microbiol. 72:2809–2814.

3. Joeger MC, Kleenhammer TR. 1986. Characterization and purification of helvetin J and evidence for a chromosomally determined bacteriocin produced by Lactobacillus helveticus 481. J. Bacteriol. 167:439–446.

4. Barrett E, Hayes M, O’Connor P, Gardiner G, Fitzgerald GF, Stanton C, Ross RP, Hill C. 2007. Salivaricin P: one of a family of two component anti-listerial bacteriocins produced by intestinal isolates of Lactobacillus salivarius. Appl. Environ. Microbiol. 73:3719–3723.

5. Dunne C, Murphy I, Flynn S, O’Mahony L, O’Halloran S, Feeney M, Morrissey D, Thornton G, Fitzgerald G, Daly C, Kielcy, Quiely EM, O’Sullivan GC, Shanahan F, Collins JK. 1999. Probiotics: from myth to reality. Demonstration of functionality in animal models of disease and in human clinical trials. Antonie Van Leeuwenhoek 76:279–292.

6. Li Y, Canchoya G, Fang F, Rafis E, Ryan KA, van Pijkeren JP, van Sinderen D, O’Toole PW. 2007. Distribution of mega-plasmids in Lactobacillus salivarius and other lactobacilli. J. Bacteriol. 189:6128–6139.

7. Martín R, Jiménez E, Olivares E, Marin ML, Fernández L, Xaus J, Rodríguez JM. 2006. Lactobacillus salivarius CECT 5713, a potential probiotic strain isolated from infant feces and breast milk of a mother-child pair. Int. J. Food Microbiol. 112:35–43.

8. Neville BA, O’Toole PW. 2010. Probiotic properties of Lactobacillus salivarius and closely related Lactobacillus species. Future Microbiol. 5:759–774.

9. Timmerman HM, Niers LE, Ridwan BU, Koning CJ, Mulder L, Akkermans LM, Rombouts FM, Rijkers GT. 2007. Design of a multispecies probiotic mixture to prevent infectious complications in critically ill patients. Clin. Nutr. 26:450–459.

10. Walsh MC, Gardiner GE, Hart OM, Lawlor PG, Daly M, Lynch B, Richert BT, Radcliffe S, Giblin L, Hill C, Fitzgerald GF, Stanton C, Ross P. 2008. Predisposition of a bacteriocin-producing Lactobacillus salivarius component of a five-strain probiotic in the porcine ileum and effects on host immune phenotype. FEMS Microbiol. Ecol. 64:317–327.

11. Arroyo R, Martin V, Maldonado A, Jiménez E, Fernández L, Rodríguez JM. 2010. Treatment of infectious mastitis during lactation: antibiotics versus oral administration of Lactobacilli isolated from breast milk. Clin. Infect. Dis. 50:1551–1558.

12. Jiménez E, Fernández L, Maldonado A, Martin R, Olivares M, Xaus J, Rodríguez JM. 2008. Oral administration of Lactobacillus strains isolated from breast milk as an alternative for the treatment of infectious mastitis during lactation. Appl. Environ. Microbiol. 74:4650–4655.

13. Lara-Villoslada F, Sierra S, Díaz-Ropero MP, Olivares M, Xaus J. 2007. Safety assessment of the human milk-isolated probiotic Lactobacillus salivarius CECT5713. J. Dairy Sci. 90:3583–3589.

14. Maldonado J, Lara-Villoslada F, Sierra S, Sempere L, Gómez M, Rodríguez JM, Boza J, Xaus J, Olivares M. 2010. Safety and tolerance of the human milk strain Lactobacillus salivarius CECT5713 in 6-month-old children. Nutrition 26:1082–1087.

15. Sierra S, Lara-Villoslada F, Sempere L, Olivares M, Boza J, Xaus J. 2010. Intestinal and immunological effects of daily oral administration of Lactobacillus salivarius CECT5713 to healthy adults. Anaerobe 16:195–200.

16. Siverin FD, O’Connor PM, Steadman LS. 2006. L. salivarius UCC118 is a novel bacteriocin-producing Lactobacillus salivarius subsp. salivarius UCC118. Microbiol. 148:973–984.

17. Cho YJ, Cha J, Kim JH, Lim YS, Ham JS, Kang DK, Chun J, Paik HD, Kim GB. 2011. Genome sequence of Lactobacillus salivarius GI-24, a bacteriostatic strain isolated from healthy adult intestine. J. Bacteriol. 193:5012–5017.

18. Flynn S, van Sinderen D, Thornton GM, Holo H, Nes IF, Collins JK. 2002. Characterization of the genetic loci responsible for the production of ABP-118, a novel bacteriocin produced by the probiotic bacterium Lactobacillus salivarius subsp. salivarius CECT5713. Microbiol. 148:6973–6982.

19. Pilasombut K, Sakpuarum T, Wijayawal K, Witthawatana A, Zendo T, Fujita K, Nakayama J, Sonomoto K. 2006. Purification and amino acid sequence of a bacteriocin produced by Lactobacillus salivarius K7 isolated from chicken intestine. Songklanakarin J. Sci. Technol. 28:121–131.

20. Vera Pingitore E, Hétbert EM, Nader-Macías ME, Sesma F. 2009. Characterization of salivaricin CRL 1328, a two-peptide bacteriocin produced by Lactobacillus salivarius CRL 1328 isolated from the human vagina. Res. Microbiol. 160:401–408.

21. Cataloluk O. 2001. Molecular characterization of the gene encoding for the salivaricin B activity and its flanking sequences. Turk. J. Biol. 25:379–386.

22. Murphy EF, Cotter PD, Hogan A, O’Sullivan O, Joyce A, Fouhy F, Clarke SF, Marques TM, O’Toole PW, Stanton C, Quiely EM, Daly C, Ross PR, O’Doherty RM, Shanahan F. 2013. Divergent metabolic outcomes arising from targeted manipulation of the gut microbiota in diet-induced obesity. Gut 62:220–226.

23. Rouleut-Bisson E, Sturmue MH, Jeffery IB, O’Donnell MM, Neville BA, Forde BM, Claesson MJ, Harris H, Gardiner GE, Casey PG, Lawlor PG, O’Toole PW, Ross RP. 2012. Effect of Lactobacillus salivarius bacteriocin Abp118 on the mouse and pig intestinal microbiota. PLoS One 7:e31113. doi:10.1371/journal.pone.0031113.

24. O’Shea EF, Gardiner GE, O’Connor PM, Mills S, Ross RP, Hill C. 2009. Characterization of enterocin- and salivaricin-producing lactic acid bacteria from the mammalian gastrointestinal tract. FEMS Microbiol. Lett. 291:124–134.

25. Claesson MJ, Li Y, Leahy S, Chanchaya C, van Pijkeren JP, Cerdeño-Tárraga AM, Parkhill J, Flynn S, O’Sullivan GC, Collins JK, Higgins D, Shanahan F, Fitzgerald GF, van Sinderen D, O’Toole PW. 2006. Multiplication genome architecture of Lactobacillus salivarius. Proc. Natl. Acad. Sci. U. S. A. 103:6718–6723.

26. Wang G, Li X, Wang Z. 2009. AP2D: the updated antimicrobial peptide database and its application in peptide design. Nucleic Acids Res. 37:D933–D937.

27. Tailor RH, Acland DP, Attenborough S, Cammue BP, Evans IJ, Osborn RW, Ray JA, Rees SB, Broekaert WF. 1997. A novel family of small
cysteine-rich antimicrobial peptides from seed of *Impatiens balsamina* is derived from a single precursor protein. J. Biol. Chem. 272:24480–24487.

31. Perego M, Glaser P, Minutello A, Strauch MA, Leopold K, Fischer W. 1995. Incorporation of d-alanine into lipoteichoic acid and wall teichoic acid in *Bacillus subtilis*. Identification of genes and regulation. J. Bacteriol. 177:2958–15606.

32. Peschel A, Otto M, Jack RW, Kalbacher H, Jung G, Götz F. 1999. Inactivation of the dlt operon in *Staphylococcus aureus* confers sensitivity to defensins, protegrins, and other antimicrobial peptides. J. Biol. Chem. 274:8405–8410.

33. Abi Khattar Z, Rejasse A, Destoumieux-Garzon D, Escoubas JM. 2001. *Staphylococcus aureus* strain S5G11 to antimicrobial peptides. Int. J. Med. Microbiol. 289:313–322.

34. Kramer NE, Hasper HE, van den Bogaard PT, Morath S, de Kruijff B, Kramer NE, van Hijum SA, Knol J, Kok J, Kuipers OP. 2008. Increased D-α-lanlylation of lipoteichoic acid and a thickened septum are main determinants in the nisin resistance mechanism of *Lactococcus lactis*. Microbiology 154:1755–1762.

35. Kramer NE, van Hijum SA, Knol J, Kok J, Kuipers OP. 2006. Transcriptome analysis reveals mechanisms by which *Lactococcus lactis* acquires nisin resistance. Antimicrob. Agents Chemother. 50:1753–1761.

36. Säss P, Bierbaum G. 2009. Native γsR mutation supports the susceptibility of *Staphylococcus aureus* strain S5G11 to antimicrobial peptides. Int. J. Med. Microbiol. 289:313–322.

37. Michelis J, Dirix G, Vanderleyden J, Xi C. 2001. Processing and export of peptide pheromones and bacteriocins in gram-negative bacteria. Trends Microbiol. 9:164–168.

38. Nes IF, Diep DB, Håvarstein LS, Brurberg MB, Håvarstein LS, Brurberg MB, Eijsink V, Holo H. 2009. Biosynthesis of bacteriocins in lactic acid bacteria. Antonie Van Leeuwenhoek 97:113–128.

39. Dubrac S, Bisicchia P, Devine KM, Rea MC, Ross RP, Cotter PD, Hill C, O’Shea EF, O’Connor PM, Cotter PD, Hill C, Rea MC, Ross RP, Cotter PD, Hill C. 2010. Studies with bioengineered nisin peptides highlighting the broad-spectrum potency of nisin V. Microbiol. 74:479–496.

40. McGrath S, Fitzgerald GF, van Sinderen D. 2001. Improvement and optimization of two engineered phage resistance mechanisms in *Lactococcus lactis*. Trends Microbiol. 9:175–180.

41. Dobson A. 2011. The impact of the broad-spectrum antimicrobial peptide, lacticin 3147 on complex microbial communities. Ph.D. thesis. University College Cork, Cork, Ireland.

42. Fitzgerald JR. 2007. Targeted gene disruption for the analysis of virulence of *Staphylococcus aureus*. Methods Mol. Biol. 391:103–112.

43. Luchansky JB, Moineau S, Klaenhammer TR. 2008. Application of electroporation for transfer of plasmid DNA to *Lactobacillus*, *Leuconostoc*, *Listeria*, *Pediococcus*, *Bacillus*, *Staphylococcus*, *Enterococcus* and Propionibacterium. Microbiol. 3:637–646.

44. Park SF, Stewart GS. 1990. High-efficiency transformation of *Listeria monocytogenes* by electroporation of penicillin-treated cells. Gene 94:129–132.

45. Sambrook J, Fritsch EF, Maniatis T. 1989. Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.

46. Kent RM, Guinan CM, O’Connor PM, Fitzgerald GF, Hill C, Stanton C, Ross RP. 2012. Production of the antimicrobial peptides casecin A and B by *Bacillus* isolates growing on sodium caseinate. Lett. Microbiol. 35:141–148.